A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder

Citation
Te. Wilens et al., A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder, AM J PSYCHI, 156(12), 1999, pp. 1931-1937
Citations number
56
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Psychiatry,"Clinical Psycology & Psychiatry","Neurosciences & Behavoir
Journal title
AMERICAN JOURNAL OF PSYCHIATRY
ISSN journal
0002-953X → ACNP
Volume
156
Issue
12
Year of publication
1999
Pages
1931 - 1937
Database
ISI
SICI code
0002-953X(199912)156:12<1931:APCCTO>2.0.ZU;2-6
Abstract
Objective:: Despite the increasing recognition of attention deficit hyperac tivity disorder (ADHD) in adults, there is a paucity of controlled pharmaco logical trials. Recent reports have suggested the potential usefulness of c holinergic agents for ADHD. To this end, the authors completed a controlled study of ABT-418, a novel cholinergic activating agent, for the treatment of adults with ADHD. Method: This was a double-blind, placebo-controlled, r andomized, crossover trial that compared a transdermal patch of ABT-418 (75 mg/day) to placebo in adults who met DSM-IV criteria for ADHD. There were two 3-week treatment periods separated by 1 week of washout. Results: Of th e 32 subjects enrolled in the study (88% were men; mean age=40 years, SD=9) , 29 completed the study. At the endpoint of each active arm (last observat ion carried forward), a significantly higher proportion of subjects was con sidered improved while receiving ABT-418 than while receiving placebo (40% versus 13%). Similarly, at endpoint there was a significantly greater reduc tion in ADHD symptom checklist scores (28% versus 15%). Symptoms reflective of attention, and subjects with less severe ADHD, responded more robustly to ABT-418. Treatment with ABT-418 was relatively well tolerated; dizziness and nausea were the most frequently reported adverse effects. Conclusions: The results of this investigation indicate that ABT-418, a nicotinic analo g, may be a potentially useful agent for the treatment of ADHD.